University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
NCT Number: NCT01711918
To provide oral domperidone to patients between the ages of 18 and 60 years of age, according to the investigator's judgment, a prokinetic effect is needed for the relief of severe gastroparesis. We have defined severe gastroparesis as 1) positive gastric emptying scintigraphy (more than 10% residue at 4 hours), 2) nausea, 3) early satiety, 4) abdominal pain. We will recruit patients for two years and the patients will be given domperidone for up to two years.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Iowa City, Iowa, 52242, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral tablet; dose is 10mg per tablet given up to 3 times daily.
Time frame: Baseline and End of study (2 years or last visit if patient withdraws)
A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.
Time frame: Baseline and End of study (2 years or last visit if patient withdraws)
A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.
Time frame: Baseline and End of study (2 years or last visit if patient withdraws)
A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.
Time frame: Baseline and End of study (2 years or last visit if patient withdraws)
A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.
Time frame: Baseline and End of study (2 years or last visit if patient withdraws)
A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.
Ron Schey
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06899217
Abdominal Pain, Digestive System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT07474415
Digestive System Diseases, Functional Dyspepsia
Columbus, Ohio, United States
View Trial DetailsNCT05832151
Diabetic Gastroparesis, Digestive System Diseases
Dothan, Alabama, United States
View Trial DetailsNCT04028492
Diabetic Gastroparesis, Digestive System Diseases
Birmingham, Alabama, United States
View Trial Details